Robert Lockwood
Family Medicine · Yukon, OKNPI 1265488829
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,353 and has fallen 78.0% since, to $298 in 2025.
Across 347 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$688
- Novo Nordisk$595
- Pfizer$541
- Lilly USA, LLC$438
- Boehringer Ingelheim$340
- Amgen$315
- plus $3K from 34 others
Across 2,544 payments — averaging $3389.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$5M
- Pfizer$740K
- Janssen Research & Development, LLC$720K
- Bavarian Nordic A/s$619K
- GSK$416K
- Johnson & Johnson$350K
- plus $736K from 10 others
What the payments were for
- Food & beverage$6,02698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 36 | $688 |
| Novo Nordisk | 36 | $595 |
| Pfizer | 31 | $541 |
| Lilly USA, LLC | 29 | $438 |
| Boehringer Ingelheim | 19 | $340 |
| Amgen | 20 | $315 |
| GSK | 19 | $313 |
| AstraZeneca | 20 | $311 |
| AbbVie(2 entities) | 13 | $261 |
| Johnson & Johnson | 16 | $254 |
| Harmony Biosciences LLC | 6 | $250 |
| Merck | 16 | $246 |
| Eisai Inc. | 10 | $218 |
| Bayer | 11 | $185 |
| Abbott | 8 | $147 |
| Therapeuticsmd, Inc. | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $97 |
| Lundbeck LLC | 3 | $92 |
| Dexcom, Inc. | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Nevro Corp. | 1 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Astellas Pharma US Inc | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Shield Therapeutics Inc | 1 | $36 |
| Alk-abello, Inc | 2 | $30 |
| Boston Scientific | 1 | $30 |
| Amarin Pharma, Inc. | 2 | $29 |
| Corcept Therapeutics | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$6,126 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $32,227 |
| MounjaroTirzepatide | 16 | $16,793 |
| FarxigaDapagliflozin Propanediol | 12 | $6,789 |
| XareltoRivaroxaban | 11 | $6,278 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,188 |
| Gabapentin | 39 | $1,085 |
| Sertraline Hcl | 26 | $1,077 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $975 |
| Tamsulosin Hcl | 17 | $779 |
| Cyclobenzaprine Hcl | 43 | $605 |
| Tizanidine Hcl | 31 | $592 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $541 |
| Pregabalin | 27 | $479 |
| Tramadol Hcl | 35 | $465 |
| Celecoxib | 21 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $340 | $32,22740 claims |
| Lilly USA, LLCMounjaro | $438 | $16,79316 claims |
| AstraZenecaFarxiga | $311 | $6,78912 claims |
| Johnson & JohnsonXarelto | $254 | $6,27811 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,07726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Yukon
- Marion StudebakerYukon$13K
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.